From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search



A drug used to treat non-small cell lung cancer that has spread to other parts of the body and is anaplastic lymphoma kinase (ALK) positive. It is used in patients whose cancer has gotten worse during treatment with or who cannot take crizotinib (a type of anticancer drug). Brigatinib blocks certain proteins made by the ALK gene. Blocking these proteins may stop the growth and spread of cancer cells. Brigatinib is a type of tyrosine kinase inhibitor. Also called Alunbrig.

Clinical use of Brigatinib

Brigatinib is a tyrosine kinase receptor inhibitor and antineoplastic agent used in the therapy of selected forms of advanced non-small cell lung cancer. 


Liver safety of Brigatinib

Brigatinib is associated with a moderate rate of transient elevations in serum aminotransferase levels during therapy but has yet to be linked to instances of clinically apparent acute liver injury

Mechanism of action of Brigatinib

Brigatinib (bri ga' ti nib) is a small molecule tyrosine kinase receptor inhibitor with potent activity against anaplastic lymphoma kinase (ALK) that is rearranged and mutated in some cancers including approximately 5% of non-small cell lung cancer (NSCLC).  The mutated, rearranged ALK promotes unregulated cell growth and proliferation.  Brigatinib has been found to inhibit mutated ALK in cell culture and in several clinical trials was found to induce objective responses in a proportion of patients with refractory, advanced NSCLC that are ALK-positive. 

FDA approval information for Brigatinib

Brigatinib was approved for use in the United States in 2017 in patients with ALK-positive, metastatic NSCLC who have progressed despite therapy with first generation ALK inhibitors (such as crizotinib). 

Dosage and administration for Brigatinib

Brigatinib is available in tablets of 30, 90 and 180 mg under the brand name Alunbrig.  The recommended dose is 90 to 180 mg daily, continued until disease progression or intolerable toxicity occurs.  side effects are common and can be dose limiting.  Common adverse events include fatigue, nausea, diarrhea, headache and cough.  Less common but potentially severe side effects include severe pulmonary toxicity, interstitial lung disease, myopathy, bradycardia and embryo-fetal toxicity. Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ


Cost and Coupons - Brigatinib

Reviews for Brigatinib

Learn more about Brigatinib

Latest research - Brigatinib

Clinical trials

External links

Medicine icon
Medicine icon

This WikiMD article Brigatinib is a stub. If you are familiar with the topic Brigatinib, you can help us. Paid editors welcome!


Brigatinib is part of WikiMD's free ^articles!

^Brigatinib (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Overweight?. W8MD's physician weight loss & sleep medicine program can HELP. Philadelphia lose weight. NYC lose weight Tele weight loss available